Mencoboni M, Olivieri R, Vannozzi MO, Schettini G, Viazzi F, Ghio R. Docetaxel Pharmacokinetics with Pre- and Post-Dialysis Administration in a Hemodyalized Patient.
Chemotherapy 2006;
52:147-50. [PMID:
16636537 DOI:
10.1159/000092903]
[Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2004] [Accepted: 07/29/2005] [Indexed: 11/19/2022]
Abstract
BACKGROUND
Docetaxel has a proven significant activity against breast, non-small cell lung, ovarian, head and neck, and hormone refractory prostate cancer. Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination. We conducted this study to elucidate the feasibility and safety of the use of docetaxel in hemodialysis patients.
PATIENT AND METHODS
In a 72-year-old hormone refractory prostate cancer patient on hemodialysis for diabetic nephropathy for 3 years, a first dose (35 mg/m(2) iv) of docetaxel was completed 30 min before starting dialysis, while a second dose was administered 30 min after completion of a different hemodialysis session. Pharmacokinetic analysis was performed following both infusions.
RESULTS
No apparent differences could be seen in the plasma concentration-time curves of docetaxel administered before or after dialysis. The patient experienced no significant toxicity after either administration of docetaxel.
CONCLUSIONS
Docetaxel is safe in dialysis patients and does not require dose reduction. Dialysis does not remove this drug from blood.
Collapse